Rating Change
Citigroup analysts reiterated a Buy rating on Krystal Biotech, Inc. (NASDAQ:KRYS) on August 04, 2026.
reiterateNASDAQ:KRYS
Citigroup Reiterates Buy Rating on Krystal Biotech, Inc. (KRYS)
Rating Change Citigroup analysts reiterated a Buy rating on Krystal Biotech, Inc. (NASDAQ:KRYS) on August 04, 2026. Market Context Krystal Biotech, Inc.
Market Context
Krystal Biotech, Inc. operates in the Healthcare sector. The stock currently trades at $324.77 with a market capitalization of $7.2B. The stock has gained 138.6% over the past 52 weeks.
Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Krystal Biotech, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Krystal Biotech, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 04, 2026 | Citigroup | Buy | N/A |
| Jul 14, 2026 | B of A Securities | Buy | N/A |
| Jun 18, 2026 | TD Cowen | Buy | N/A |
| Jun 16, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 01, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View KRYS Stock Page
Frequently Asked Questions
What does a Buy rating mean for KRYS?
A Buy rating from Citigroup reflects the analyst's outlook on Krystal Biotech, Inc. (NASDAQ:KRYS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the KRYS forecast page.